Pfizer receives positive CHMP opinion for conversion of Paxlovid conditional marketing authorisation to full marketing authorisation in the European Union

Pfizer

27 January 2023 - Pfizer today announced that the CHMP of the EMA has recommended converting the conditional marketing authorisation for Paxlovid (nirmatrelvir tablets and ritonavir tablets) to standard (or full) marketing authorisation for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

The recommendation to convert the conditional marketing authorisation to full marketing authorisation is based on the totality of available efficacy, safety, and quality data provided by Pfizer.

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder